Medpace Holdings, Inc. (MEDP) on Decifer

Decifer ranks MEDP number 110 of 270 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 68% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 20% a year, profits grew 20% over the past year, and growth is speeding up, not slowing down.
• It keeps a healthy share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• It is riding an active market tailwind and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• A pristine business with returns near 68% and revenue growing about 20%, but momentum of 17 out of 35 and no funded catalyst cap the growth case.

The current read

The evidence on MEDP lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Pharma Innovation Financing & Outsourced R&D: Rising cost and complexity of clinical development is pushing biopharma toward outsourced trial execution and non-dilutive royalty capital.

Read the full MEDP research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.